TSH Biopharm Corporation Limited (TPEX:8432)

Taiwan · Delayed Price · Currency is TWD

51.70

+0.90 (1.77%)

Apr 20, 2026, 1:14 PM CST

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Adjustment and Elimination	-86.40M	-64.07M	-	-	-
Domestic Cardiovascular and Gastrointestinal Drugs	656.95M	628.51M	497.31M	647.38M	413.48M
Domestic Cardiovascular and Gastrointestinal Drugs Growth	4.52%	26.38%	-23.18%	56.57%	-7.68%
Investment	765.97M	551.28M	313.61M	93.69M	-
Investment Growth	38.94%	75.78%	234.74%	-	-
Total	1.34B	1.12B	810.92M	741.07M	413.48M
Total Growth	19.79%	37.59%	9.43%	79.23%	-7.68%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Taiwan	1.34B	1.12B	810.92M	741.07M	413.48M
Taiwan Growth	19.79%	37.59%	9.43%	79.23%	-7.68%
Total	1.34B	1.12B	810.92M	741.07M	413.48M
Total Growth	19.79%	37.59%	9.43%	79.23%	-7.68%

Source: S&P Global Market Intelligence.